That will never happen. She filters out any positive statements, which is
what makes her posts so disturbing.

L.

It seems to me I heard somewhere that Sharon Hope wrote in article
<vqudnTht2uLWYpLfRVn-iw@comcast.com>:

No, that is not what you see.  What you see is evidence that Dr. Golomb
is not a statin warrior who can be trotted out whenever you need a
spokesperson.  Surely you realize that she is pointing out a *positive*
effect of statins.  If you accept her as an expert then you will need to
accept her positive statements (and there are quite a few) as well as
her negative ones.

I see you, too, now use Dr. Golomb as a credible source who is an expert in
statins - as does the AHA.

It seems to me I heard somewhere that Zee wrote in article
<1108234197.229913.277760@f14g2000cwb.googlegroups.com>:

{Statins, Alzheimer's, and strokes]

You may be surprised to learn that Dr. Beatrice Golomb explains why
statins may actually reduce the number of strokes; from a study she
reported at a Conference in November, 2004:
[http://www.atacand.com/index.asp?did=3430&aid=42076&l1=5&l2=1&mid=l2-5-1]

[Start]
Dr. Golomb indicated that the study had limitations; for example, most
patients were normotensive and the sample of hypertensive patients was
of insufficient size to extrapolate these findings to that population.
Furthermore, the effect of statins on blood pressure across various
doses was not studied. Nevertheless, she concluded that statins could
reduce blood pressure and that this effect could help to explain why
several studies have reported that these agents can reduce the risk of
stroke, despite cholesterol not being an important risk factor for
cerebrovascular disease.
[End]

What happens to those of us who took them for years is quite different
from what happens in clincial trials. Frankie's husband for example
would have been deemed a raging success 6 months out, two years out;
and he is not alone. We hear from hundreds; we get corroboration from
their physicians and the pattern is the same. Over and over and over.
No; anecdote is not as good as fact. But it certainly raises question
in any reasonable person.

statins, stroke and cognition:
http://www.geriatrictimes.com/g040618.html

Second, the large trials enrolled people at high risk for
cardiovascular disease who experience benefit from statins to nonfatal
stroke, which may lead to improvements in cognition that may help to
balance out harms to cognition from other mechanisms. Although there
are trends toward increases in fatal stroke with statins in most of the
large statin trials, those who have died cannot complete cognitive
surveys. The impact on total number of strokes was unaffected in the
PROSPER trial with its sole focus on the elderly population. In the
PROSPER trial, the number of reduced transient ischemic attacks and
nonfatal strokes was actually matched by a similar number of increased
fatal strokes.

Finally, the HPS used what is termed an "active run-in." For six weeks,
participants considered for enrollment were placed on simvastatin, and
those who were not fully compliant were dropped from the study.
Participants who perceived problems on the drug, including cognitive
problems, may have dropped the study themselves or skipped pills
intentionally. In addition, participants who developed memory problems
may have had trouble remembering to take the pills even if they did not
recognize deterioration in cognitive function. This run-in process may
have excluded participants who developed cognitive problems on the
drug, selecting only those who did not experience problems. Over
one-third of those who were interested in enrolling were excluded
following this compliance run-in.

Because statins reduce nonfatal stroke (and cognition is obviously not
measured in people who have experienced fatal stroke), benefits by
statins for cognitive function in those in whom a stroke was averted
might be expected. It must be emphasized that the randomized trial
evidence has, to date, uniformly failed to show cognitive benefits by
statins and has supported no effect or frank and significant harm to
cognitive function.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Frisoni GB, Fratiglioni L, Fastbom J et al. (1999), Mortality in
nondemented subjects with cognitive impairment: the influence of
health-related factors. Am J Epidemiol 150(10):1031-1044.

Golomb BA, Kane T, Dimsdale JA (2004), Severe irritability associated
with statin cholesterol-lowering drugs. QJM 97(4):229-235.

Golomb BA, Yang E, Denenberg J, Criqui M (2003), Statin-associated
adverse events. P95. Presented at the 43rd Annual Conference on
Cardiovascu

King DS, Jones DW, Wofford MR et al. (2001), Cognitive impairment
associated with atorvastatin. Presented at the American College of
Clinical Pharmacy Spring Practice and Research Forum. Salt Lake City;
April 22-25.

King DS, Wilburn AJ, Wofford MR et al. (2003), Cognitive impairment
associated with atorvastatin and simvastatin. Pharmacotherapy
23(12):1663-1667.

Korten AE, Jorm AF, Jiao Z et al. (1999), Health, cognitive, and
psychosocial factors as predictors of mortality in an elderly community
sample. J Epidemiol Community Health 53(2):83-88.

The article makes it clear that there are conflicting studies: some
show
no protection against dementia, others do. Obviously, much more
research
is needed.

Who wouldn't hope that there *might* be some benefit from statins
against
this most debilitating disease, alzheimers? <<

COMMENT:

While we're visiting this subject, let us note that Alzheimer's is
responsible for maybe half of dementia only. A large fraction of the
other half is caused by mini-strokes and vascular disease. And of
course, there's a 20 to 30% overlap of people who have both problems.

Of these, Alzheirmer's is the process I would LEAST expect statins to
interfere with. They might, but they might not.  However, statins have
already show impressive anti-stroke capability, even in people with
normal cholesterol levels. So if statins do not work in slowing or
preventing progression of Alzheimer's, this in no way means we've ruled
out their role in preventing "dementia."

SBH

Another misleading subject line.....

The article makes it clear that there are conflicting studies: some show
no protection against dementia, others do. Obviously, much more research
is needed.

Who wouldn't hope that there *might* be some benefit from statins against
this most debilitating disease, alzheimers?

L.

Many of us who have been exposed first-hand to the devastating cognitive
adverse effects of statins have been tremendously skeptical of the "Can
statins prevent Alz?????" headlines, which appeared at a time that
conveniently offset articles in the popular media that exposed the memory
loss caused by statins.

We doubters also questioned how the studies would differentiate between Alz
and statin-induced memory loss.

As it turns out, this latest study shows that statins do NOT prevent
Alzheimer's:

     Statins Don't Protect Against Dementia: Study
     http://today.reuters.co.uk/news/newsArticle.aspx?type=healthNews&storyID=2005-02
-10T211401Z_01_B371082_RTRIDST_0_HEALTH-STATINS-DEMENTIA-DC.XML
     Reuters.uk, UK - 5 hours ago
     NEW YORK (Reuters Health) - The use of cholesterol-lowering drugs
belonging to the statin family, such as Lipitor or Pravacol, does not seem
to have any effect ...

     Statins Don't Protect Against Dementia: Study
     http://www.reuters.com/newsArticle.jhtml?type=healthNews&storyID=7598600
     Reuters - 5 hours ago
     NEW YORK (Reuters Health) - The use of cholesterol-lowering drugs
belonging to the statin family, such as Lipitor or Pravacol, does not seem
to have any effect ...

     Statins Don't Protect Against Dementia: Study
     http://abcnews.go.com/Health/wireStory?id=488976
     ABC News - 5 hours ago
     Feb 10, 2005 - NEW YORK (Reuters Health) - The use of
cholesterol-lowering drugs belonging to the statin family, such as Lipitor
or Pravacol, does not seem ...

Statins Don't Protect Against Dementia: Study
Thu Feb 10, 2005 9:15 PM GMT

NEW YORK (Reuters Health) - The use of cholesterol-lowering drugs belonging
to the statin family, such as Lipitor or Pravacol, does not seem to have any
effect on the risk of dementia or Alzheimer's disease, according to findings
from a new study.

This supports the results of another study, but run counter other study
findings that have linked statin use with a reduced risk of dementia.

The current study involved elderly residents living in Cache County, Utah,
who were evaluated for statin use and dementia between 1995 and 1997 and
then again between 1998 and 2000.

Dr. John C. S. Breitner, from the VA Puget Sound Health Care System in
Seattle, and colleagues report their findings in the Archives of General
Psychiatry.

Of the 4,895 subjects evaluated at the initial assessment, 355 had dementia,
including 200 with Alzheimer's disease. In this analysis, statin use was
associated with a 56-percent reduction in risk of dementia.

During 3-year follow-up, 185 of 3308 at-risk survivors were diagnosed with
dementia, including 104 with Alzheimer's disease. In this analysis, statin
use at the start of the study or at follow-up had no effect on the risk of
dementia or Alzheimer's disease.

One explanation for the different findings could be that after dementia sets
in, patients may simply be less likely to use statins, along with other
drugs.

Studies with sufficient statistical power are needed to assess the effect of
statin use on dementia risk, the authors note. "Until such research is able
to demonstrate more promising results, however, we suggest that costly
randomized trials of statins are premature."

SOURCE: Archives of General Psychiatry, February 2005.